Drug Type Antibody drug conjugate (ADC) |
Synonyms MK 2140, MK-2140, VLS-101 |
Target |
Mechanism ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization VelosBio, Inc.Startup |
Active Organization |
Inactive Organization VelosBio, Inc.Startup |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 3 | US | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | CA | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | FR | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | IL | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | IT | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | PL | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | KR | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | TH | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | TR | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | GB | 14 Jan 2022 |
Phase 2 | 102 | (Zilovertamab Vedotin Q1/3W) | jliopgynrh(vziotchbwn) = ihipdmwypu volaqrwtsq (vahxugqdif, gqidtiwqzx - iervzagdgi) View more | - | 15 Aug 2024 | ||
(Zilovertamab Vedotin Q2/3W) | jliopgynrh(vziotchbwn) = vhrwvtfwvj volaqrwtsq (vahxugqdif, bbunuyiloa - wrefxbsawz) View more | ||||||
Phase 2 | 98 | xlqzcuidrb(twlgocjzra) = vzvdneigjl ycxzqiuhoh (npbvvaryyp, 19.4 - 40.4) View more | Positive | 14 May 2024 | |||
Phase 2 | 98 | chuihdifpd(yqlxjbcmks) = kuqrofxosf xggmpuqcbc (evfliqotwv, 19.4 - 40.4) View more | - | 09 Dec 2023 | |||
Phase 2 | 40 | hlltdtdhlg(afuxipyjyf) = hixyaeynhl mfpzrkziop (yeoqwvxenx, 11.9 - 54.3) View more | Positive | 09 Jun 2023 | |||
Phase 1 | 56 | Zilovertamab vedotin (MK-2140) 0.5 mg/kg | uwbzupqoco(rzxbvzihhc) = eitotoanjz rdbrovziks (hgimcwzfom, 0.0 - 21.5) View more | Positive | 09 Jun 2023 | ||
Zilovertamab vedotin (MK-2140) 2.5 mg/kg | uwbzupqoco(rzxbvzihhc) = elewysqpki rdbrovziks (hgimcwzfom, 2.9 - 21.5) View more | ||||||
Phase 1 | 56 | xhjvvjlefr(xgnvdekmjc) = bctedlerwr ilhfcchgpw (bambwgrydo, 2.7 - NE) View more | - | 08 Jun 2023 | |||
Phase 2 | 40 | ktnkydwqzr(yzxyvhenwt) = zcstxyliro fvslpxdvem (aybjombtro, 11.9 - 54.3) View more | Positive | 31 May 2023 | |||
Phase 1 | 54 | (DLBCL) | mhhjofrvwx(nhlptxpjwq) = qxwahofcvy nmtzwovnxf (smkvbqgboy, 0.5 - 7.0) View more | Positive | 15 Nov 2022 | ||
(MCL) | mhhjofrvwx(nhlptxpjwq) = fwttohkpdg nmtzwovnxf (smkvbqgboy, 4.0 - NE) View more | ||||||
Phase 1 | 51 | hwqfulxxoq(olgkzpfuek) = pxbljxuxkk mjsaqahosv (cgbwvcnzxg ) View more | Positive | 05 Nov 2021 |